Brief: Fusen Pharmaceutical Company Posts HY Profit Attributable Of RMB53.5 Mln
31/08/2018 14:32
Aug 31 (Reuters) - Fusen Pharmaceutical Company Ltd
1652.HK :
* DECLARED AN INTERIM DIVIDEND OF RMB0.54 CENTS PER ORDINARY
SHARE
* HY REVENUE UP 17.4% TO RMB271.9 MILLION
* HY PROFIT ATTRIBUTABLE RMB53.5 MILLION VERSUS RMB52.1
MILLION
Source text: http://bit.ly/2NDvGc2
Further company coverage: 1652.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusen Pharmaceutical
See all newsBrief: Fusen Pharmaceutical Logs HY Loss Attributable RMB13.6 Million
Brief: Fusen Pharmaceutical Says Doxazosin Mesylate Extended-Release Tablets Approved For Marketing In China
Brief: Fusen Pharmaceutical Says Peramivir Injection First Neuraminidase Inhibitor Approved In China For Intravenous Influenza Treatment
Brief: Fusen Pharmaceutical Says Investors To Contribute RMB300 Mln For 34% Stake Subscription Of Henan Fusen Pharmaceutical
Brief: Fusen Pharmaceutical Says Piracetam Injection Approved For Marketing By NMPA